Cancer and New Drugs · global
Challenges Remain After Trial Meets Goal: Limited Benefit From BioNTech’s Breast Cancer ADC, With Lung Risks Shaping Next Steps
Although a Phase 3 trial delayed disease progression, BioNTech described the improvement as limited and disclosed serious and fatal lung events. The termination of a colorectal cancer vaccine trial mentioned in the same update was a decision already announced in August; a pancreatic cancer combination therapy study remains ongoing.
A trial of a new cancer drug can meet its primary objective and still have some way to go before becoming a valuable treatment option. In its third-quarter business update on November 3, BioNTech disclosed that although its breast cancer antibody-drug conjugate (ADC), trastuzumab pamirtecan, delayed disease progression in a Phase 3 trial, the company described the improvement as limited. Serious and fatal cases of interstitial lung disease also occurred in the trial, making the balance between efficacy and risk a central question for further development.
Jointly developed with DualityBio and designated BNT323/DB-1303, the drug targets HER2. The global Phase 3 DYNASTY-Breast02 trial enrolled patients with hormone receptor-positive, HER2-low metastatic breast cancer. Results showed a statistically significant improvement in progression-free survival compared with investigator’s choice of chemotherapy. However, this endpoint measures the time before disease progression or death and cannot be directly equated with extending life; overall survival data were not yet mature at this analysis.
Safety makes these results harder to interpret solely on the basis of having “met the goal.” The company said the incidence of interstitial lung disease was higher than in previous trials of the drug. Most cases were Grade 1 or 2, while a small proportion of patients experienced serious to fatal Grade 3–5 events. The announcement did not provide specific incidence rates, the number of deaths, or the magnitude of the progression-free survival improvement. It is therefore not yet possible to quantify how much additional time patients gained or the corresponding risk they faced.
On this basis, BioNTech judged that the drug’s potential benefit for patients may be limited in the current treatment landscape for this type of breast cancer. The company and DualityBio are reviewing breast cancer and endometrial cancer data together as they discuss further development and plans for a biologics license application. These remain under evaluation; neither a filing nor an end to development has been confirmed.
The same update also mentioned the early termination of a Phase 2 colorectal cancer trial of the personalized mRNA cancer vaccine autogene cevumeran, but that decision had already been announced on August 28. The BNT122-01 trial enrolled high-risk patients with stage II or III disease who still had detectable circulating tumor DNA (ctDNA) in their blood after surgery and chemotherapy. It compared vaccine monotherapy with close observation to investigate whether the vaccine could reduce the risk of recurrence.
According to the August announcement, the independent data safety monitoring committee found a numerical imbalance in overall survival between the two groups and considered it unlikely that continuing the trial would change the efficacy conclusions. It therefore recommended stopping treatment and terminating the study. The announcement did not specify the direction or magnitude of the imbalance, and the committee identified no new safety signals. The available information is insufficient to infer that the vaccine increased the risk of death, much less to generalize this result to all mRNA cancer therapies.
Autogene cevumeran, jointly developed with Genentech, remains under evaluation in IMcode003, a Phase 2 trial in pancreatic ductal adenocarcinoma. The study combines immune checkpoint inhibition with chemotherapy, completed enrollment in August, and was unaffected by the termination of the colorectal cancer trial. Different cancer types, patient selection criteria, and combination treatment approaches each require clinical validation. For both development programs, complete efficacy and safety data will provide the basis for deciding the next steps.